Patient reported outcomes after MIRPN to treat acute pancreatitis
Research type
Research Study
Full title
QUALITY OF LIFE IN PATIENTS AFTER MINIMAL ACCESS RETROPERITONEAL PANCREATIC NECROSECTOMY (MIPRN) TO TREAT ACUTE PANCREATITIS - AN EXPLORATORY STUDY.
IRAS ID
196044
Contact name
Piotr Zelga
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust
Duration of Study in the UK
0 years, 11 months, 26 days
Research summary
Acute pancreatitis (AP) is one of the most common diseases of the gastrointestinal tract and in the UK it results in nearly 20 000 hospital admissions per year. Approximately 20% of patients experience a much more severe illness associated with a high number of complications and even death in 15% to 30%. That is due to the development of pancreatic necrosis, particularly if this becomes secondarily infected. Surgical removal of necrotic pancreatic tissue (necrosectomy) has led to fall in related death rate to 20% in recent years. Surgical treatments for infected pancreatic necrosis may be through open or minimally invasive (percutaneous i.e. via needle-puncture of the skin or transgastric/transduodenal - endoscopic access through the gastric or duodenal wall) approaches. Minimal invasive techniques aim to decrease number of complications associated with surgical intervention through one long incision (open) and improve the survival of patients with this life-threatening condition. In particular a transcutaneous approach by minimal access retroperitoneal pancreatic necrosectomy (MIRPN) has demonstrated significant benefits over open necrosectomy. In particular, it is recognized to have fewer complications, although a number of surgical interventions are typically needed rather than a single operation.\nHowever, little is known regarding the long-term consequences of experiencing an episode of severe acute pancreatitis and its treatment on a patient`s function, symptoms and quality of life. \nPatients who have suffered from severe acute pancreatitis are subject to tremendous emotional, physical, and financial burdens, all of which will impact on their overall health status and career/financial prospects. Therefore, it is increasingly clear that the impact of an illness or treatment on patient reported outcomes (PRO) including health related quality of life are important when evaluating the long term effects of this disease and its treatment. There are currently no studies describing patient reported outcomes, including quality of life in patients who have undergone MIRPN.\nThis study will describe patient reported outcomes in participants who have undergone MIRPN following successful treatment and discharge from hospital. PROs will be assessed using general and disease specific measures.
REC name
North West - Preston Research Ethics Committee
REC reference
16/NW/0224
Date of REC Opinion
25 Apr 2016
REC opinion
Further Information Favourable Opinion